Enhancement of antinociception by coadminstration of minocycline and a non-steroidal anti-inflammatory drug indomethacin in nave mice and murine models of LPS-induced thermal hyperalgesia and monoarthritis

BMC Musculoskeletal Disorders

Volumn 11, Issue , 2010, Pages

  Abu Ghefreh, Ala'A Ahmed ^a   Masocha, Willias ^a  

^a KUWAIT UNIVERSITY   (Kuwait)

Author keywords

[No Author keywords available]

Indexed keywords

CAY 10404; CYCLOOXYGENASE 1 INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; FRI 122047; INDOMETACIN; LIPOPOLYSACCHARIDE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; UNCLASSIFIED DRUG; ANALGESIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANKLE; ANTIINFLAMMATORY ACTIVITY; ANTINOCICEPTION; ARTICLE; BAGG ALBINO MOUSE; C57BL 6 MOUSE; GAIT; HINDLIMB; HOT PLATE TEST; HYPERALGESIA; LIMB; LOW DRUG DOSE; MONARTHRITIS; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PAIN; PRESSURE; RHEUMATOID ARTHRITIS; VIDEORECORDING; WEIGHT BEARING; WEIGHT CHANGE; ANIMAL; ARTHRITIS; C57BL MOUSE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DOSE RESPONSE; DRUG COMBINATION; DRUG POTENTIATION; TREATMENT OUTCOME;

ANALGESICS; ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ARTHRITIS; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; HYPERALGESIA; INDOMETHACIN; LIPOPOLYSACCHARIDES; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MINOCYCLINE; TREATMENT OUTCOME;

EID: 78649528666     PISSN: None     EISSN: 14712474     Source Type: Journal    
DOI: 10.1186/1471-2474-11-276     Document Type: Article

References (56)

1. Tetracyclines: nonantibiotic properties and their clinical implications. AN Sapadin R Fleischmajer, J Am Acad Dermatol 2006 54 2 258 265 10.1016/j.jaad.2005.10.004 16443056
2. Minocycline in the treatment of rheumatoid arthritis: relationship of serum concentrations to efficacy. M Kloppenburg H Mattie N Douwes BA Dijkmans FC Breedveld, J Rheumatol 1995 22 4 611 616 7791150
3. Benefits and risks of minocycline in rheumatoid arthritis. P Langevitz A Livneh I Bank M Pras, Drug Saf 2000 22 5 405 414 10.2165/00002018-200022050- 00007 10830256
4. Should tetracycline treatment be used more extensively for rheumatoid arthritis? Metaanalysis demonstrates clinical benefit with reduction in disease activity. M Stone PR Fortin C Pacheco-Tena RD Inman, J Rheumatol 2003 30 10 2112 2122 14528503
5. Current evidence for the management of rheumatoid arthritis with synthetic disease-modifying antirheumatic drugs: a systematic literature review informing the EULAR recommendations for the management of rheumatoid arthritis. C Gaujoux-Viala JS Smolen R Landewe M Dougados TK Kvien EM Mola M Scholte-Voshaar P van Riel L Gossec, Ann Rheum Dis 2010 69 6 1004 1009 10.1136/ard.2009.127225 20447954
6. Minocycline and pentoxifylline attenuate allodynia and hyperalgesia and potentiate the effects of morphine in rat and mouse models of neuropathic pain. J Mika M Osikowicz W Makuch B Przewlocka, Eur J Pharmacol 2007 560 2-3 142 149 10.1016/j.ejphar.2007.01.013 17307159
7. Inhibition of microglial activation attenuates the development but not existing hypersensitivity in a rat model of neuropathy. V Raghavendra F Tanga JA DeLeo, J Pharmacol Exp Ther 2003 306 2 624 630 10.1124/jpet.103.052407 12734393
8. Characterization of the antinociceptive and anti-inflammatory activities of doxycycline and minocycline in different experimental models. LF Bastos LA Merlo LT Rocha MM Coelho, Eur J Pharmacol 2007 576 1-3 171 179 10.1016/j.ejphar.2007.07.049 17719028
9. Arthritis imaging using a near-infrared fluorescence folate-targeted probe. WT Chen U Mahmood R Weissleder CH Tung, Arthritis Res Ther 2005 7 2 310 317 10.1186/ar1483 15743478
10. Assessment of weight bearing changes and pharmacological antinociception in mice with LPS-induced monoarthritis using the Catwalk gait analysis system. W Masocha SS Parvathy, Life Sci 2009 85 11-12 462 469 10.1016/j.lfs.2009.07.015 19683012
11. The pivotal role of tumour necrosis factor alpha in the development of inflammatory hyperalgesia. FQ Cunha S Poole BB Lorenzetti SH Ferreira, Br J Pharmacol 1992 107 3 660 664 1472964
12. TNF-alpha and IL-1beta mediate inflammatory hypernociception in mice triggered by B1 but not B2 kinin receptor. TM Cunha WA Verri Jr SY Fukada AT Guerrero T Santodomingo-Garzon S Poole CA Parada SH Ferreira FQ Cunha, Eur J Pharmacol 2007 573 1-3 221 229 10.1016/j.ejphar.2007.07.007 17669394
13. Bradykinin initiates cytokine-mediated inflammatory hyperalgesia. SH Ferreira BB Lorenzetti S Poole, Br J Pharmacol 1993 110 3 1227 1231 8298813
14. Acute but not chronic stimulation of glial cells in rat spinal cord by systemic injection of lipopolysaccharide is associated with hyperalgesia. LH Guo HJ Schluesener, Acta Neuropathol 2006 112 6 703 713 10.1007/s00401-006-0135-z 17021756
15. Functional interplay between gelatinases and hyperalgesia in endotoxin-induced localized inflammatory pain. RS Talhouk L Hajjar R Abou-Gergi CJ Simaa'n G Mouneimne NE Saade B Safieh-Garabedian, Pain 2000 84 2-3 397 405 10.1016/S0304-3959(99)00238-9 10666546
16. Tumour necrosis factor-alpha, interleukin-1beta and interleukin-8 induce persistent mechanical nociceptor hypersensitivity. D Sachs FQ Cunha S Poole SH Ferreira, Pain 2002 96 1-2 89 97 10.1016/S0304-3959(01)00433-X 11932065
17. Bradykinin B1 and B2 receptors, tumour necrosis factor alpha and inflammatory hyperalgesia. S Poole BB Lorenzetti JM Cunha FQ Cunha SH Ferreira, Br J Pharmacol 1999 126 3 649 656 10.1038/sj.bjp.0702347 10188975
18. A peripheral sympathetic component in inflammatory hyperalgesia. M Nakamura SH Ferreira, Eur J Pharmacol 1987 135 2 145 153 10.1016/0014-2999(87) 90606-6 2884117
19. Interleukin-1beta induces substance P release from primary afferent neurons through the cyclooxygenase-2 system. A Inoue K Ikoma N Morioka K Kumagai T Hashimoto I Hide Y Nakata, J Neurochem 1999 73 5 2206 2213 10537081
20. The role of anti-inflammatory drugs in the treatment of osteoarthritis: a European viewpoint. M Dougados, Clin Exp Rheumatol 2001 19 6 Suppl 25 9 14 11695258
21. Basic therapy for rheumatoid arthritis: nonsteroidal anti-inflammatory drugs. KF Daoud CG Jackson HJ Williams, Compr Ther 1999 25 8-10 427 433 10.1007/BF02944294 10520445
22. The inflammatory process of gout and its treatment. BN Cronstein R Terkeltaub, Arthritis Res Ther 2006 8 Suppl 1 3 10.1186/ar1908 16820042
23. Current therapeutic practices in spondyloarthropathies. MB Yunus, Compr Ther 1988 14 2 54 64 3278840
24. Inflammation and the mechanism of action of anti-inflammatory drugs. J Vane R Botting, Faseb J 1987 1 2 89 96 3111928
25. Cyclo-oxygenase-2: pharmacology, physiology, biochemistry and relevance to NSAID therapy. JA Mitchell TD Warner, Br J Pharmacol 1999 128 6 1121 1132 10.1038/sj.bjp.0702897 10578123
26. Peripheral analgesic sites of action of anti-inflammatory drugs. SH Ferreira, Int J Clin Pract Suppl 2002 128 2 10 12166614
27. Anti-inflammatory and side effects of cyclooxygenase inhibitors. H Suleyman B Demircan Y Karagoz, Pharmacol Rep 2007 59 3 247 258 17652824
28. The spinal actions of nonsteroidal anti-inflammatory drugs and the dissociation between their anti-inflammatory and analgesic effects. K McCormack, Drugs 1994 47 Suppl 5 28 45 discussion 46-27. 10.2165/00003495-199400475-00006 7525183
29. Involvement of brain serotonergic system in the antinociceptive action of acetylsalicylic acid in the rat. LA Pini M Sandrini G Vitale, Inflamm Res 1995 44 1 30 35 10.1007/BF01630485 7664027
30. Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol. Experimental studies in the rat. R Bjorkman, Acta Anaesthesiol Scand Suppl 1995 103 1 44 7725891
31. Effect of rofecoxib on nociception and the serotonin system in the rat brain. M Sandrini G Vitale LA Pini, Inflamm Res 2002 51 3 154 159 10.1007/PL00000287 12005206
32. Mechanisms of non-opioid analgesics beyond cyclooxygenase enzyme inhibition. M Hamza RA Dionne, Curr Mol Pharmacol 2009 2 1 1 14 10.2174/1874467210902010001 19779578
33. Ethical guidelines for investigations of experimental pain in conscious animals. M Zimmermann, Pain 1983 16 2 109 110 10.1016/0304-3959(83)90201-4 6877845
34. The analgesic effect profile of FR122047, a selective cyclooxygenase-1 inhibitor, in chemical nociceptive models. T Ochi Y Motoyama T Goto, Eur J Pharmacol 2000 391 1-2 49 54 10.1016/S0014-2999(00)00051-0 10720634
35. Dual, but not selective, COX-1 and COX-2 inhibitors, attenuate acetic acid-evoked bladder irritation in the anaesthetised female cat. A Wibberley GP McCafferty C Evans RM Edwards JP Hieble, Br J Pharmacol 2006 148 2 154 161 10.1038/sj.bjp.0706715 16547526
36. Design and syntheses of diarylisoxazoles: novel inhibitors of cyclooxygenase-2 (COX-2) with analgesic-antiinflammatory activity. AG Habeeb PNP Rao EE Knaus, Drug Dev Res 2000 51 273 286 10.1002/ddr.9 (Pubitemid 32197301)
37. Automated quantitative gait analysis during overground locomotion in the rat: its application to spinal cord contusion and transection injuries. FP Hamers AJ Lankhorst TJ van Laar WB Veldhuis WH Gispen, J Neurotrauma 2001 18 2 187 201 10.1089/08977150150502613 11229711
38. Minocycline, a tetracycline derivative, is neuroprotective against excitotoxicity by inhibiting activation and proliferation of microglia. T Tikka BL Fiebich G Goldsteins R Keinanen J Koistinaho, J Neurosci 2001 21 8 2580 2588 11306611
39. Minocycline impedes African trypanosome invasion of the brain in a murine model. W Masocha ME Rottenberg K Kristensson, Antimicrob Agents Chemother 2006 50 5 1798 1804 10.1128/AAC.50.5.1798-1804.2006 16641452
40. Excessive matrix metalloproteinase activity in diabetes: inhibition by tetracycline analogues with zinc reactivity. ME Ryan A Usman NS Ramamurthy LM Golub RA Greenwald, Curr Med Chem 2001 8 3 305 316 11172685
41. The gelatinase inhibitory activity of tetracyclines and chemically modified tetracycline analogues as measured by a novel microtiter assay for inhibitors. L Paemen E Martens K Norga S Masure E Roets J Hoogmartens G Opdenakker, Biochem Pharmacol 1996 52 1 105 111 10.1016/0006-2952(96)00168-2 8678893
42. Inhibitory action of minocycline on lipopolysaccharide-induced release of nitric oxide and prostaglandin E2 in BV2 microglial cells. SS Kim PJ Kong BS Kim DH Sheen SY Nam W Chun, Arch Pharm Res 2004 27 3 314 318 10.1007/BF02980066 15089037
43. Total hip replacement. A comparison between cemented (Charnley) and non-cemented (HP Garches) fixation by clinical assessment and objective gait analysis. E Olsson I Goldie A Wykman, Scand J Rehabil Med 1986 18 3 107 116 3787206
44. Surgical correction of leg alignment in unilateral knee osteoarthrosis reduces the load on the hip and knee joint bilaterally. L Weidenhielm OK Svensson L Brostrom Lk, Clin Biomech (Bristol, Avon) 1995 10 4 217 221 10.1016/0268-0033(95)91401-Y 11415556
45. The influence of tetracyclines on T cell activation. M Kloppenburg CL Verweij AM Miltenburg AJ Verhoeven MR Daha BA Dijkmans FC Breedveld, Clin Exp Immunol 1995 102 3 635 641 10.1111/j.1365-2249.1995.tb03864.x 8536384
46. The effect of minocycline in rat models of inflammatory arthritis: correlation of arthritis suppression with enhanced T cell calcium flux. KL Sewell F Breedveld E Furrie J O'Brien C Brinckerhoff R Dynesius-Trentham Y Nosaka DE Trentham, Cell Immunol 1996 167 2 195 204 10.1006/cimm.1996.0027 8603428
47. Minocycline in rheumatoid arthritis. A 48-week, double-blind, placebo-controlled trial. MIRA Trial Group. BC Tilley GS Alarcon SP Heyse DE Trentham R Neuner DA Kaplan DO Clegg JC Leisen L Buckley SM Cooper,, et al. Ann Intern Med 1995 122 2 81 89 7993000
48. A perspective on the use of minocycline for rheumatoid arthritis. SM Cooper, J Clin Rheumatol 1999 5 4 233 237 discussion 237-238 10.1097/00124743-199908000-00011 19078393
49. Reduction of prostaglandin E2 concentrations in synovial fluid of patients suffering from rheumatoid arthritis following tiaprofenic acid or indomethacin treatment. TJ Daymond FJ Rowell, Drugs 1988 35 Suppl 1 4 8 10.2165/00003495-198800351-00004 3162870
50. Minocycline protects PC12 cells from ischemic-like injury and inhibits 5-lipoxygenase activation. Y Song EQ Wei WP Zhang L Zhang JR Liu Z Chen, Neuroreport 2004 15 14 2181 2184 10.1097/00001756-200410050-00007 15371729
51. Potentiation of antinociceptive effect of NSAIDs by a specific lipooxygenase inhibitor, acetyl 11-keto-beta boswellic acid. M Bishnoi CS Patil A Kumar SK Kulkarni, Indian J Exp Biol 2006 44 2 128 132 16480179
52. Minocycline treatment inhibits microglial activation and alters spinal levels of endocannabinoids in a rat model of neuropathic pain. L Guasti D Richardson M Jhaveri K Eldeeb D Barrett MR Elphick SP Alexander D Kendall GJ Michael V Chapman, Mol Pain 2009 5 35 10.1186/1744-8069-5-35 19570201
53. A role for endocannabinoids in indomethacin-induced spinal antinociception. H Guhring M Hamza M Sergejeva M Ates CE Kotalla C Ledent K Brune, Eur J Pharmacol 2002 454 2-3 153 163 10.1016/S0014-2999(02)02485-8 12421642
54. Cannabinoids reduce hyperalgesia and inflammation via interaction with peripheral CB1 receptors. JD Richardson S Kilo KM Hargreaves, Pain 1998 75 1 111 119 10.1016/S0304-3959(97)00213-3 9539680
55. Antinociceptive activity of the endogenous fatty acid amide, palmitylethanolamide. A Calignano G La Rana D Piomelli, Eur J Pharmacol 2001 419 2-3 191 198 10.1016/S0014-2999(01)00988-8 11426841
56. Endogenous anandamide and cannabinoid receptor-2 contribute to electroacupuncture analgesia in rats. L Chen J Zhang F Li Y Qiu L Wang YH Li J Shi HL Pan M Li, J Pain 2009 10 7 732 739 10.1016/j.jpain.2008.12.012 19409856